Lívia Guimarães , Juliana Piedade , Tamires Rocha , Caroline Baldin , Lívia Victor , Gustavo Pereira
{"title":"哌拉西林-他唑巴坦治疗肝硬化患者的严重血小板减少症","authors":"Lívia Guimarães , Juliana Piedade , Tamires Rocha , Caroline Baldin , Lívia Victor , Gustavo Pereira","doi":"10.1016/j.liver.2023.100170","DOIUrl":null,"url":null,"abstract":"<div><p>portal hypertension and bacterial infections are frequent in cirrhosis and their coexistence may render this population susceptible to severe drug-induced thrombocytopenia. We describe frequency, clinical characteristics and prognosis of Piperacillin/Tazobactan associated thrombocytopenia. 84 patients [Child 10±1, MELD 18±8; SIRS and ACLF in 28% and 24%] were included. Thrombocytopenia developed in 12 patients and was associated with a higher frequency of bleeding from multiple sites and platelet transfusion. Severe/persistent thrombocytopenia correlated with in-hospital mortality. In conclusion, development of thrombocytopenia is frequent in cirrhotic patients treated with Piperacillin/Tazobactan and this complication, especially in most severe forms, is associated with high morbidity and mortality.</p></div>","PeriodicalId":100799,"journal":{"name":"Journal of Liver Transplantation","volume":"12 ","pages":"Article 100170"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Severe thrombocytopenia in cirrhotic patients treated with Piperacillin-Tazobactam\",\"authors\":\"Lívia Guimarães , Juliana Piedade , Tamires Rocha , Caroline Baldin , Lívia Victor , Gustavo Pereira\",\"doi\":\"10.1016/j.liver.2023.100170\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>portal hypertension and bacterial infections are frequent in cirrhosis and their coexistence may render this population susceptible to severe drug-induced thrombocytopenia. We describe frequency, clinical characteristics and prognosis of Piperacillin/Tazobactan associated thrombocytopenia. 84 patients [Child 10±1, MELD 18±8; SIRS and ACLF in 28% and 24%] were included. Thrombocytopenia developed in 12 patients and was associated with a higher frequency of bleeding from multiple sites and platelet transfusion. Severe/persistent thrombocytopenia correlated with in-hospital mortality. In conclusion, development of thrombocytopenia is frequent in cirrhotic patients treated with Piperacillin/Tazobactan and this complication, especially in most severe forms, is associated with high morbidity and mortality.</p></div>\",\"PeriodicalId\":100799,\"journal\":{\"name\":\"Journal of Liver Transplantation\",\"volume\":\"12 \",\"pages\":\"Article 100170\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Liver Transplantation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666967623000326\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Liver Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666967623000326","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Severe thrombocytopenia in cirrhotic patients treated with Piperacillin-Tazobactam
portal hypertension and bacterial infections are frequent in cirrhosis and their coexistence may render this population susceptible to severe drug-induced thrombocytopenia. We describe frequency, clinical characteristics and prognosis of Piperacillin/Tazobactan associated thrombocytopenia. 84 patients [Child 10±1, MELD 18±8; SIRS and ACLF in 28% and 24%] were included. Thrombocytopenia developed in 12 patients and was associated with a higher frequency of bleeding from multiple sites and platelet transfusion. Severe/persistent thrombocytopenia correlated with in-hospital mortality. In conclusion, development of thrombocytopenia is frequent in cirrhotic patients treated with Piperacillin/Tazobactan and this complication, especially in most severe forms, is associated with high morbidity and mortality.